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Abstract
Cell death plays an important role in tumorigenesis, growth, and progression and
affects the efficiency of chemotherapy to a great extent. Apoptosis is usually regarded
as the principal mechanism of chemotherapy-induced cell death. However, the
dysregulation of apoptosis occurs commonly in many cancers, which lowers the
effectiveness of therapy and allows cells to survive. The mechanisms by which cells
acquire this resistance to chemotherapy are not fully understood. Several studies
uncovered alternative cell death pathways that are mechanistically distinct from
apoptosis. These pathways, including autophagy and necrosis, represent potential
targets for novel cancer treatment. By modulating the key regulatory molecules
involved in the different types of cell death, more effective and less toxic chemother‐
apy might be developed. In this chapter, we describe the signaling pathways and the
molecular events that are involved in these three major forms of programmed cell
death. Additionally, we also discuss the emerging therapies targeting these cell death
pathways as new strategies against cancer.
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1. Introduction
According to the World Health Organization, cancers figure among the leading causes of death
worldwide, accounting for 8.2 million deaths in 2012 [1]. The annual number of cancer cases
are expected to rise from 14 million in 2012 to 22 million within the next two decades [1]. Cancer
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can affect everyone - the young and the old, the rich and the poor, men and women - and poses
a tremendous burden on patients, families, and societies. A substantial number of cancer
patients experience a significant reduction in their quality of life due to physical pain, mental
anguish, and economic hardship. Scientists and doctors are continuously making efforts to
find better and more effective therapies against cancer. Currently, strategically targeted cancer
therapies are emerging as treatments, which use drugs or other substances, such as tyrosine
kinase inhibitors and apoptosis inducing agents, to interfere with specific molecules and
processes involved in cancer cell growth and survival [2].
In multicellular organisms, the number of cells is tightly regulated to attain a balance between
cell proliferation and death. Maintaining this balance is crucial for normal development and
tissue size homeostasis [3]. Cell death is a fundamental process that not only plays a pivotal
role in the regulation of normal physiological development and tissue balance but also acts as
a defense mechanism against diseases such as cancer [4]. Over the past two decades, our
knowledge of cell death and the mechanisms of its regulation have increased dramatically.
Programmed cell death (PCD) is a principal mechanism of tumor suppression and is triggered
in nonmalignant cells to eliminate unnecessary, aged, or damaged cells that may otherwise be
harmful to the body [5]. Of note, apoptosis, autophagy, and programmed necrosis are the three
main forms of PCD, easily distinguished by their morphological characteristics within the cell
[6, 7]. Additionally, senescence and mitotic catastrophe (MC) are two other cell death mecha‐
nisms, often triggered in cancer cells and tissues in response to anticancer drugs [8]. Cell
senescence, a state of permanent cell-cycle arrest characterized by specific changes in mor‐
phology and gene expression that differentiate it from reversible cell cycle arrest, is also
considered as a type of cell death in the context of cancer therapy [9].
Accumulated data suggest that various chemotherapeutic agents can kill tumor cells through
the induction of apoptosis [10]. Dysregulation of the apoptotic pathways can not only promote
tumorigenesis [11, 12] but also render cancer cells resistant to chemotherapy. The ability of
cancer cells to avoid apoptosis and continue to proliferate is one of the fundamental hallmarks
of cancer and is a major target of cancer therapy development [12].Development of novel
molecules that activate apoptosis by targeting both the intrinsic and extrinsic apoptotic
pathways will advance our understanding of the mechanisms behind tumor cell proliferation,
which may also lead to the development of effective cancer therapies. Autophagy is an
evolutionarily conserved process that maintains cellular homeostasis by controlling protein
and organelle turnover. It serves as critical adaptive response that recycles energy and
nutrients during periods of starvation and stress to enable cell survival. Studies have shown
that autophagy contributes to the adaptation of tumor cells to adverse microenvironments [13]
and chemotherapy [13]. Autophagy may represent a major impediment to successful cancer
therapy; therefore, targeting autophagy is considered a promising strategy in clinical cancer
treatment. However, other studies have shown that deficiency in adequate autophagy results
in various spontaneous tumors in mouse model [14], indicating a tumor suppressive role of
autophagy in the process of tumorigenesis. It seems that autophagy plays dual roles as both
promoter and suppressor in tumorigenesis. The dynamic role of autophagy in tumor devel‐
opment appears mainly dependent on tumor stage [15]. It is important to elucidate the
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mechanisms by which autophagy influences tumorigenesis and treatment response. Analysis
of autophagic signaling may identify novel therapeutic targets. Necrosis is generally consid‐
ered a passive response to massive cellular damage. However, accumulating evidence
supports the existence of programmed necrosis, which involves cell swelling, organelle
dysfunction, and cell lysis [16, 17]. Given the fact that many cancers have defective apoptosis
machinery, it is reasonable to consider the pros and cons of activating other cell death
pathways, such as necrosis, senescence and MC, and assess their therapeutic potential.
In this chapter, we discuss three major forms of PCD at molecular, cellular, and physiological
levels. We also discuss the regulation mechanisms of these cell death pathways. Finally, the
emerging therapies and strategies targeting these cell death pathways in the treatment of
cancers are examined.
2. Apoptosis
The term “apoptosis” originates from Greek words apo, which means “since, ” and ptosis, which
means “dropping off, ” and it refers to leaves falling off trees or petals dropping off flowers.
It was first coined by Kerr et al. in 1972 and used to describe a regulated form of cell death with
specific morphological features, which is different from the necrotic cell death resulting from
acute tissue injury [18]. Since then, apoptosis has become one of the most extensively studied
forms of PCD that plays a critical role in normal biological processes, such as embryonic
development, immune response, tissue homeostasis, and cell turnover [19], as well as in a
variety of pathological conditions including cancer [20]. Studies have shown that a cell
undergoing apoptosis can be described by a series of characteristic morphological changes,
including cell shrinkage, membrane blebbing, chromatin condensation, and nuclear fragmen‐
tation [21]. In addition to the morphological changes, biochemical changes happening during
apoptosis have also been revealed, and the three main ones are (1) the activation of caspases,
(2) the breakdown of DNA and protein, and (3) the modifications of cell surface markers
tagging the apoptotic cells for recognition by phagocytic cells [22].
Tissue homeostasis is maintained by an elaborate balance between cell growth by proliferation
and/or survival on one side and cell death via apoptosis and other pathways on the other side.
Any changes in the contribution of cell growth versus cell death can seriously affect the tissue
homeostasis leading to human diseases. Accumulated evidence indicates that defect in
apoptosis can contribute to cancer or onset of autoimmune responses, while excessive cell
death can cause acute or chronic degenerative diseases, immunodeficiency, and infertility [23].
Under normal conditions, apoptosis represents a safeguard mechanism to prevent tumori‐
genesis, which indicates that evasion or resistance to apoptosis is a pivotal feature of cancer
[24]. Alterations in cancer cells, which lead to impaired apoptotic signaling, not only promote
tumor formation, progression, and metastasis but also contribute to treatment resistance [6-8,
24]. Thus, a better understanding of the molecular events that are involved in the regulation
of apoptosis and their dysregulation in human cancers is expected to provide novel strategies
for cancer therapy.
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2.1. Two main signaling pathways involved in drug-induced apoptosis
Apoptosis can be triggered by various stimuli from outside or inside of the cells, for example,
by ligation of cell surface receptors, by DNA damage as a results of treatment with cytotoxic
drugs or irradiation, by a lack of survival signals or by developmental death signals. These
death signals of diverse origins eventually converge to activate a series of cysteine aspartyl-
specific proteases (caspases) through two main pathways, namely, extrinsic (death receptor)
and intrinsic (mitochondrial) pathways [25]. Caspases are central to the mechanisms of
apoptosis, which cleave key cellular proteins and dismantle the cells (Figure 1). Given the
death-causing effects of caspase activation, these two pathways are strictly and closely
regulated at each step. Apart from the two pathways mentioned, endoplasmic reticulum (ER)-
mediated apoptosis is a lesser known third pathway [26].
Figure 1. The extrinsic and intrinsic apoptosis signaling pathways. The extrinsic pathway primarily involves the acti‐
vation of procaspase 8 by death receptors (e.g., TNFR1 and Fas/Apo 1), whereas the intrinsic pathway involves the
release of factors from mitochondria, such as cytochrome c, that forms a complex with APAF1 and procaspase 9, re‐
sulting in the cleavage and activation of procaspase 9. In mammals, either active caspase 8 or caspase 9 is capable of
activating effector caspases such as caspase 3 or caspase 7, which then cleave apoptotic substrates leading to apoptosis.
A link between the extrinsic and intrinsic pathways is observed in certain cells. This involves the cleavage of the Bcl-2
family member Bid by caspase 8, leading to the release of cytochrome c from the mitochondria and activation of cas‐
pase 9. For detailed signaling pathways, please see Sections 2.1.1-2.1.3.
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Apoptosis in response to cancer therapy proceeds through the activation of the core apoptotic
machinery, including the receptor and the mitochondrial signaling pathway [10]. In many
tumor cell types, the main signaling pathway leading from drug-induced damage to cell death
involves the mitochondrial release of proapoptotic molecules under the control of the B-cell
lymphoma 2 (Bcl-2) family of proteins. However, death receptors of the tumor necrosis factor
receptor (TNFR) superfamily, mainly CD95 (APO-1/Fas), have also been shown to play a role
in linking drug-induced damage to the apoptotic machinery and modulating drug response.
2.1.1. Extrinsic (death receptor) pathway
The extrinsic apoptotic pathway is activated by the binding of death ligands to cell surface
death receptors, which transmit extracellular death signals to the intracellular apoptotic
machinery to elicit cell death [27]. Although several death receptors have been identified, the
best known death receptors belong to the TNFR superfamily, including TNFRs, CD95
(Fas/Apo 1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors
[28]. These receptors become activated once bound by their cognate ligands such as TNF, CD95
(Fas), and TRAIL, which in turn results in death receptor aggregation, and recruitment of
various adaptor proteins to the intracellular death domains (DD) of the death receptors and
formation of death-inducing signaling complex (DISC). In this complex, Fas-associated death
domain (FADD) recruits other DD- and/or death effector domain (DED)-containing proteins,
such as procaspase 8 and procaspase 10, via homotypic death domain interactions (Figure 1)
[29]. In contrast, TNF receptor-associated death domain (TRADD) recruits proteins leading to
the formation of two complexes [30]. For example, TNFR1 binds to and forms complex I with
TRADD, TNF receptor-associated factors 2 and 5 (TRAF2/5), receptor interacting protein 1
(RIP1), and the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) (Figure 1). This
complex is important for the TNF-induced activation of NF-κB and MAPKs and the subsequent
transcription of antiapoptotic genes. In certain circumstance, RIP1 is deubiquitinated by
cylindromatosis and leads to the dissociation of RIP1 and TRADD from complex I. RIP1 and
TRADD then form complex II with FADD, caspase 8, and/or caspase 10, which is analogous
to the DISC induced by FasL and TRAIL (Figure 1) [4, 31, 32]. The activation of caspases 8 and
10 leads to the activation of the downstream caspase cascade to mediate apoptosis. In some
cells, named type I cells, the activation of effector caspases, such as caspases 3, 6, and 7, by
caspase 8/10 alone can induce apoptosis [33]. However, in type II cells, activated caspase 8/10
triggers the activation of intrinsic apoptotic pathway by the cleavage of the Bcl-2-homology 3
(BH3)-only protein Bid. Cleaved Bid is myristoylated to form tBid and translocates to the
mitochondria membrane, which promotes the oligomerization of Bax and Bak and causes the
release of apoptotic mediators from the mitochondria (Figure 1) [34, 35].
2.1.2. Regulation of the extrinsic pathway
Caspase 8 is the predominant initiator caspase in the extrinsic pathway, which plays a pivotal
role in determining the cell fate following the death receptor activation. Therefore, the major
signals that affect the recruitment of caspase 8 and its activation can modulate this signaling
pathway. For example, cellular FADD-like interleukin-1β-converting enzyme inhibitory
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protein (cFLIP) shares significant structural similarities with caspases 8 and 10, which allows
it to compete for binding sites and thus displace caspase 8/10 in the DISC complex. cFLIP lacks
a functional caspase domain, suggesting it to be a dominant-negative inhibitor [36]. Besides
caspase 8/10, cFLIP can also bind to FADD and TRAIL receptor 5 (DR5), and this interaction
in turn prevents the formation of the DISC complex and the subsequent activation of caspase
cascade [37]. Similarly, A20-binding inhibitor of NF-κB 1 (ABIN1) exerts its antiapoptotic effect
by interfering with the interaction of RIP1 and FADD with caspase 8 [38].
cIAP1/2 contain a signature baculovirus IAP repeat (BIR), a caspase-recruitment domain
(CARD), and a really interesting new gene (RING) domain at their C-terminal that exhibits E3
ubiquitin ligase activity, which help to recruit TRAF1/2 and inhibit TNFα-apoptotic signaling.
Although cIAP1/2 are not efficient caspase 8 inhibitors, they can play a regulatory role in
extrinsic pathway through the activation of prosurvival signals, such as NF-κB pathway. This
effect was shown to result from the cIAP1/2 induction of RIP1 ubiquitination and the recruit‐
ment of TAK1, TAB2/3, and the IKK complex [39]. The NF-κB signaling pathway has been
linked to death receptor signaling because RIP, which serves as an adaptor molecule for TNFR1
in the NF-κB pathway, can be cleaved by caspases. Upon TNF receptor signaling, this modu‐
lates the balance between proapoptotic and antiapoptotic signals and may even stimulate an
autocrine “death loop” [10, 40]
Ubiquitination has been shown to regulate the activity of caspase 8. A clear example is that the
polyubiquitination of the p10 subunit of caspase 8 by a cullin3-based E3 ligase can enhance its
enzymatic activity [41]. This modification occurs after the recruitment of caspase 8 to DISC
complex and allows for the binding of active caspase 8 to the polyubiquitination-binding
protein, p62, which is thought to increase the stability of cleaved caspase 8 [41]. The deubi‐
quitinating (DUB) enzyme A20 was reportedly involved in reversing this modification [41].
2.1.3. Intrinsic (mitochondrial) pathway
The intrinsic pathway, as implied by its name, is activated by internal stimuli such as DNA
damaging agents, growth factor deprivation, oxidants, hypoxia, overload of calcium, and
microtubule targeting drugs [42]. Upon the detection of the internal stimuli, two proapoptotic
Bcl-2 family members, Bax and Bak, undergo structural changes and subsequent oligomeri‐
zation at the outer membrane of the mitochondria, leading to the induction of mitochondrial
outer membrane permeabilization (MOMP) and the release of mitochondrial cytochrome c
(Cyt-c) into the cytosol [43-46]. The released Cyt-c assembles a multiprotein caspase-activating
complex, known as the “apoptosome” [47]. The central component of the apoptosome is Apaf1
that is transiently bound by released Cyt-c in the presence of ATP or dATP, which leads to the
oligomerization of Apaf1 and then the exposure of its CARD [48]. Subsequently, Apaf1 binds
to procaspase 9 via interaction between their CARDs. In this complex, procaspase 9 dimerizes
and autoactivates. Activated caspase 9 then cleaves and activates the downstream executioner
caspases 3 and 7 to perpetrate cell death rapidly (Figure 1) [49]. Besides Cyt-c, other apoptotic
factors are also released from the mitochondrial intermembrane space into the cytoplasm such
as apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase/direct
inhibitor of apoptosis (IAP)-binding protein with low pI (Smac/DIABLO), and Omi/high
temperature requirement protein A2 (Omi/HtrA2) [50]. Smac/DIABLO and Omi/HtrA2
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promote caspase activation by neutralizing the inhibitory effects on IAPs, while AIF causes
DNA condensation [51-53]
2.1.4. Regulation of the intrinsic pathway
The intrinsic pathway is tightly regulated by the intricate interactions between pro- and
antiapoptotic members of the Bcl-2 family, which are categorized according to the organization
of their Bcl-2 homology (BH) domains: (1) antiapoptotic members such as Bcl-2, Bcl-xL, Bcl-w,
A1, and Mcl-1, which all possess the four BH1-BH4 domains and inhibit proapoptotic coun‐
terparts; (2) effector proapoptotic members such as Bax, Bak, and Bok, which all possess the
three domains BH1-BH3; and (3) BH3-only proteins, including Bid, Bad, Bim, Bik, Bmf, Hrk,
Noxa, Puma, Blk, BNIP3, and Spike, which only have the short BH3 motif and promote MOMP,
either by inhibiting antiapoptotic proteins or by activating Bax and Bak [54-56]. Antiapoptotic
Bcl-2 members block the oligomerization of Bax and Bak or their association with BH3-only
proteins, thus preventing MOMP and Cyt-c release. However, upon a cytotoxic stimulus, the
effects of antiapoptotic members are counteracted by BH3-only proteins, such as Bim and
Noxa. BH3-only proteins release Bax-Bak from inhibition and allow them to promote MOMP
and apoptosis.
The inhibitor of apoptosis protein (IAP) family represents another negative regulator of the
intrinsic apoptotic pathway. So far, eight members have been identified, including cIAP1,
cIAP2, X-linked IAP (XIAP), neuronal apoptosis inhibitory protein (NAIP), melanoma IAP
(ML-IAP), survivin, Apollon, and IAP like protein 2 (ILP2) [57]. All IAPs contain BIR domains
and 70 amino acid motifs, which are essential for antiapoptotic properties of IAPs because BIR
domains bind the active sites of caspases and inhibit proteolytic function. Indeed, XIAP,
survivin, and cIAP1/2 have been found to directly inhibit caspases 3, 7, and 9 [58]. In case of
XIAP, its BIR3 domain directly binds to the small subunit of caspase 9, while its BIR2 domain
interacts with the active-site substrate-binding pocket of caspases 3 and 7 [59, 60]. Some IAPs
such as cIAP1/2 and XIAP contain a highly conserved RING domain that possesses E3
ubiquitin ligase activity and may target effector caspases for ubiquitination and subsequent
proteasomal degradation [61, 62].
Other apoptotic factors, for example, Smac/DIABLO, when released from the mitochondrial
intermembrane space during mitochondrial apoptotic events, are able to bind to various IAPs,
mainly XIAP in a manner that displaces caspases from XIAP and enables their activation. In
addition, the binding of Smac/DIABLO to IAPs facilitates the latter to be degraded by protea‐
some [63]. However, unlike Cyt-c, the ablation of Smac/DIABLO, Omi/HtrA2, or both proteins
does not lead to the inability to activate caspases or undergo apoptosis [64-66]. This suggests
that there may be considerable redundancy in XIAP inhibition, and in fact other proteins have
also been demonstrated to inhibit XIAP [67].
3. Autophagy
The term autophagy (from the Greek auto, meaning “oneself, ” and phagy, meaning “eating”)
was first introduced by Christian de Duve based on the observation that cells were able to
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digest their own components [68]. Nowadays, autophagy is defined as a self-digestive cellular
process by which eukaryotes degrade and recycle long-lived proteins, cellular aggregates, and
damaged cellular organelles to maintain cellular homeostasis. Three types of autophagy,
macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), have been
identified to date, which could be distinguished from one another via different modes of
delivery of the cargo to the lysosome and their function. Microautophagy is a direct engulfment
of cytoplasmic components into the lysosomal lumen for degradation [69], while in CMA, a
subset of soluble cytosolic proteins containing a KFERQ motif are recognized by molecular
chaperons, including the HSPA8/HSC70 (heat shock 70 kDa protein 8), and directly translo‐
cated into lysosomes through a receptor (LAMP-2A) on the lysosomal membrane [70].
Macroautophagy is a process that is responsible for the delivery and degradation of macro‐
molecules and organelles by generating specialized cytosolic vesicles (hereafter referred to as
autophagy) [71].
Autophagy is activated under physiological and pathological conditions, such as nutrient
starvation, hypoxia, hyperthermia, and oxidative stress, and in response to drugs and
radiation. This dynamic process generates cellular energy resources that allow a cell to adapt
its metabolism to energy demand. Defects in the autophagy process lead to the accumulation
of damaged proteins and/or genomic damage and can cause diseases such as neurodegener‐
ation, infectious diseases, heart diseases, and cancers [72, 73]. Although autophagy can
suppress tumor growth, it clearly plays a role in promoting tumor cells to survive under stress
[74]. The suppression of autophagy can sensitize cancer cells to anticancer therapy [75, 76], but
under apoptosis deficiency condition, autophagy can also cause cell death through a process
termed “autophagic cell death” [72, 77].
3.1. Pathway of autophagy
After induction by a stress signal such as starvation, the process of autophagy begins with the
formation of autophagosomes, which assemble around and encapsulate the targeted proteins
or organelles, and then fuse with lysosomes to form autolysosomes for degradation. This
complex process can be divided into five major steps, namely, nucleation, elongation, matu‐
ration, fusion, and degradation, which are tightly controlled by a subset of molecules encoded
by autophagy-related genes (ATGs) (Figure 2A). The first step of autophagy is the nucleation
of the phagophore, an isolation membrane that most likely derives from the ER [78, 79]. Besides
the ER, studies have also shown that the plasma membrane and membranes of mitochondria
and Golgi are also involved in the formation of the phagophore [80, 81]. The phagophore then
extends and sequesters the substrates destined for degradation and finally forms the charac‐
teristic double membrane vesicle, known as autophagosome. The outer membrane of the
mature autophagosome then fuses with the lysosome or inner body to generate a structure
named autolysosome, where the inner membrane of autophagosome and its contents are
degraded by the activity of acidic hydrolases provided by the lysosome [82, 83]. The catabolic
products are then either recycled into different metabolic pathways or undergo further
degradation to yield energy (Figure 2A).
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Figure 2. Schematic representations of the autophagy pathway and its regulation. (A) The five major steps of autopha‐
gy, namely, nucleation, elongation, maturation, fusion, and degradation, are illustrated. Phagophore membrane elon‐
gation and subsequent sealing of the autophagosome require two ubiquitin-like conjugation systems that mediate the
formation of ATG5-ATG12 complex and LC3-II. (B) The signaling molecules and pathways involved in autophagy reg‐
ulation (see Sections 3.1-3.3 for details).
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Autophagy is a highly regulated process by ∼30 ATGs discovered hitherto in mammals.
Several signaling pathways that initiate autophagy converge at a serine/threonine protein
kinase mammalian target of rapamycin (mTOR), a key regulator of the autophagic pathway,
which inhibits  autophagy in the presence of nutrients and growth factors [84].  In mam‐
mals, the initiation of phagophore formation is regulated by a great deal of macromolecu‐
lar  complexes  or  groups  of  proteins,  including the  ULK1 kinase  and its  regulators,  the
autophagy-specific phosphatidylinositol 3-kinase (PI3K) complex, and the multi-spanning
transmembrane  protein  ATG9  [85-88].  The  PI3K  complex,  which  consists  of  the  active
enzyme VPS34, a class III PI3K, together with p150 and Beclin 1, the counterparts of yeast
Vps15  and  Vps30/Atg6,  and  ATG14,  catalyze  the  production  of  phosphatidylinositol-3-
phosphate, thereby triggering the recruitment of effectors proteins, such as double FYVE-
containing protein 1 (DFCP1) and WD-repeat domain phosphoinositide-interacting (WIPI)
family  proteins  [89-93].  The  elongation  of  the  isolation  membrane  and  the  subsequent
closure of the autophagosome require two ubiquitin-like conjugation systems. First is the
ATG12-ATG5-ATG16L system: ATG12 is conjugated to ATG5 by the ATG7 (E1-like enzyme)
and ATG10 (E2-like enzyme). The resulting ATG5-ATG12 complex interacts with ATG16L
and then oligomerizes to form a large ATG16L complex, which localizes on the outer surface
of the extending autophagosomal membrane, but it dissociates from the membrane before
autophagosome formation is completed (Figure 2A) [94]. A recent study demonstrated that
under  certain  stress  conditions,  autophagy  can  occur  independently  of  ATG5/ATG7,
suggesting  the  existence  of  an  alternative  pathway  for  autophagosome  formation  [95].
Second is the phosphatidylethanolamine (PE)-light chain 3 (LC3) system: LC3 (the mamma‐
lian homologue of yeast Atg8) is cleaved by the cysteine protease ATG4 and then conjugat‐
ed to the lipid PE by the activity of ATG7 and ATG3 (E2-like enzyme) [94, 96]. The lipidated
form of LC3 (LC3II) specifically accumulates on nascent autophagosomes and recruits cargo
adaptor proteins (also known as autophagy receptors), such as p62, Nbr1, or NIX. These
proteins,  in  turn,  recruit  cargo  from  the  cytoplasm,  for  example,  ubiquitinated  protein
aggregates and damaged organelles, to promote the closure of the autophagosome [97-99].
Once  autophagosome  formation  is  complete,  it  fuses  with  lysosomes  through  mecha‐
nisms that remain largely unknown in mammalian cells. Some regulators have been found
to be involved in the autophagosome-lysosome fusion process, including LC3, the lysoso‐
mal proteins LAMP-1 and LAMP-2, the small GTP-binding protein RAB7, and the AAA-
type ATPase SKD1 [100-102]. Autophagosome-lysosome fusion then leads to the activation
of the hydrolases and the degradation of the sequestered cargo (Figure 2A).
3.2. Signaling pathways involved in the regulation of autophagy
3.2.1. Mammalian target of rapamycin
The mTOR, a PI3K-related serine/threonine protein kinase, plays a key role in maintaining the
balance between cell growth and proliferation. It has also been found to regulate the autophagy
in response to nutrient status, growth factor signals, and cell stress [103]. In higher eukaryotes,
mTOR exists in at least two distinct protein complexes, known as mTOR complex 1 (mTORC1)
and mTOR complex 2 (mTORC2) [104, 105]. The mTORC1 consists of mTOR, mLST8 (mam‐
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malian lethal with SEC13 protein 8), RAPTOR (regulatory-associated protein of mTOR),
PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain containing mTOR-
interacting protein) and is considered to be the principal regulator of autophagy [106].
mTORC1 is downstream of PI3K and is activated in response to mitogenic stimuli or nutrient
availability. When nutrients and growth factors are available, mTORC1 inhibits autophagy by
phosphorylating ULK1-ATG13-FIP200 complex, which is required for the phagophore
formation [107, 108]. In addition, activated mTORC1 promotes mRNA translation via activat‐
ing S6K and inhibiting 4EBP1. The inhibition of mTORC1 strongly induces autophagy, for
example, rapamycin (an mTORC1 inhibitor), and potently induces autophagy even in the
presence of rich nutrients. As indicated (see Figure 2B), mTOR activity is activated by different
signaling pathways, which converge on the tuberous sclerosis complex (TSC) and the ras
homolog enriched in brain (Rheb), a small GTPase that activates mTORC1 when in its GTP-
bound state [109]. TSC, which is comprised of TSC1 (harmartin) and TSC2 (tuberin), acts as a
GTPase-activating protein (GAP) for Rheb, promoting hydrolysis of its bound GTP and thus
inhibiting Rheb and mTORC1 activity [110]. The inhibition of TSC1/2 by Akt phosphorylation
allows Rheb-GTP to accumulate and activates mTOR [111]. Phosphatase and tensin homology
(PTEN), a phosphoinositide-3 phosphatase, is a negative regulator of the PI3K/Akt pathway
and thus an inducer of autophagy [112].
3.2.2. AMP-activated protein kinase
AMP-activated protein kinase (AMPK), a serine/threonine protein kinase, is another sensor of
cellular energy status and regulates the metabolism of glucose and lipids in response to
changes in nutrient and intracellular ATP concentration. In conditions of nutrient deprivation,
reduced ATP production causes an elevated AMP/ATP ratios that activates the energy-sensing
serine/threonine kinase 1(LKB1)-AMPK signaling axis [113]. Elevated AMP/ATP ratio
activates the LKB1 and subsequently phosphorylates and activates AMPK. The activation of
AMPK mediates the phosphorylation of TSC, which results in the inactivation of mTORC1
and induction of autophagy [114, 115]. Moreover, AMPK has also been found to directly
phosphorylate RAPTOR, an activating component of mTORC1, thereby inhibits mTORC1 in
a TSC-independent manner (Figure 2B) [116].
AMPK also directly regulates autophagy through the phosphorylation and activation of ULK1.
Studies have shown that AMPK interacts with the N-terminal proline/serine (PS)-rich domain
of ULK1, and this interaction is required for the ULK1-mediated autophagy (Figure 2B) [117].
Furthermore, AMPK has been shown to associate with and directly phosphorylate ULK1 on
several amino acid sites, and this modification is required for ULK1 activation in response to
nutrient deprivation [118]. It was reported that AMPK can interact with and phosphorylate
ULK1 at Ser555, Ser637, and Thr659 and that AMPK-dependent phosphorylation of ULK1 is
involved in the localization of ATG9 and increases autophagy efficiency [119]. Similarly, Kim
et al. found that under the conditions of glucose starvation, AMPK activates ULK1 through
direct phosphorylation of ULK1 on Ser317 and Ser777, thereby activating ULK1 and promoting
autophagy [120]. By contrast, Shang et al. found that ULK1 undergoes dramatic dephosphor‐
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ylation on Ser638 and Ser758 upon starvation, and the dephosphorylation of ULK1 leads to its
dissociation from AMPK and becoming more active in autophagy induction [113, 121].
3.3. Regulation of autophagy by oncogenes and tumor suppressor
3.3.1. Bcl-2 family members
Bcl-2 family members were initially identified and characterized as regulators of apoptosis;
however, more and more evidence has revealed that the members of this family also regulate
the autophagy process. The antiapoptotic Bcl-2 family members, including Bcl-2, Bcl-xL, Bcl-
w, and Mcl-1, have been found to interact with Beclin 1 and inhibit autophagy [122-124] (see
Figure 2B). Because the overexpression of these antiapoptotic genes is commonly seen in cancer
cells, the inhibition of autophagy may promote the oncogenic properties of these Bcl-2 family
proteins. Indeed, the small interfering RNA (siRNA)-mediated knockdown of Bcl-2 can trigger
autophagy and apoptosis in tumor cells [125, 126]. The antiapoptotic proteins were found to
interact with Beclin 1 through their BH3 receptor domain and the BH3 domain of Belcin 1,
thereby inhibiting Beclin-1-dependent autophagy [122]. The disruption of such interaction by
ABT737, a BH3-mimetic agent, or the expression of other proteins with Bcl-2 homology 3 (BH3)
domain that competitively disrupt the interaction can induce autophagy [123]. Additionally,
the death-associated protein kinase, DAPK, a protein that phosphorylates Beclin 1 thereby
disrupting Beclin-1-Bcl-2 interaction and inducing autophagy, is another inducer of autophagy
that is commonly silenced by methylation in different types of human cancers.
In contrast to antiapoptotic proteins, the proapoptotic BH3-only proteins, such as BNIP3L, Bad,
Noxa, Puma, BimEL22, and Bik, can promote autophagy [127]. For example, autophagy
induced by hypoxia occurs through a hypoxia inducible factor-1 (HIF-1)-dependent transcrip‐
tional activation of BNIP3L that disrupts the interaction between Bcl-2 and Beclin 1 [128].
Furthermore, Puma, another “BH3-only” protein, induces mitochondrial autophagy in
response to mitochondrial perturbations in a Bax/Bak-dependent manner [129].
3.3.2. p53 and p53-related regulators
The p53 tumor suppressor protein is well known for its role as a transcription factor that
regulates the expression of a series of genes, contributing to cell cycle arrest, DNA damage and
repair, apoptosis, and senescence [130, 131]. Underscoring its importance in the regulation of
proliferative homeostasis, it is the most commonly mutated tumor suppressor in human cancer
[132]. In mammalian cells, p53 shuttles between the nucleus and the cytoplasm; activated p53
translocates to the nucleus and induces the expression of target genes. Although p53 is best
known as a nuclear transcription factor, studies also demonstrate that cytoplasmic p53
mediates mitochondrial outer membrane permeabilization and transcription-independent
apoptosis [133, 134].
Similarly, p53 has been shown to modulate autophagy depending on its subcellular localiza‐
tion. Nuclear p53 stimulates autophagy in a transcription-dependent fashion by modulating
the expression of a number of regulators that inhibit the mTOR pathway. For example, p53
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activates the genes encoding AMPKβ1 (a component of AMPK), TSC1/2 and PTEN, which are
all known negative regulators of mTORC1, leading to the activation of autophagy [135]. In
addition, sestrin 1 and sestrin 2, two p53 target genes, have been identified as a critical link
between p53 activation and mTORC1 activity [136]. Sestrin is induced in response to DNA
damage and oxidative stress in a p53-dependent manner and inhibits mTORC1 activity via
AMPK-mediated TSC activation (Figure 2B) [136]. Furthermore, sestrin 2 was shown to be
required for autophagy induction in response to various cellular stress conditions, including
nutrient starvation and rapamycin exposure [137]. In addition, p53 can promote autophagy in
an mTOR-independent manner via the upregulation of damage regulated autophagy modu‐
lator (DRAM), a lysosomal protein mediating autophagic cell death [138]. However, p53 can
also suppress autophagy [139], an effect attributable to cytoplasmic rather than nuclear p53
(Figure 2B). A recent study indicates that cytoplasmic p53 can regulate autophagy through
direct interaction with FIP200 [140]. In addition, several autophagy inducers, such as nutrient
starvation, rapamycin, and ER stress, stimulate proteasome-mediated degradation of p53;
hence, the inhibition of p53 degradation can suppress autophagy induced by these cellular
stress signals.
4. Necroptosis/programmed necrosis
For a long time, necrosis has been considered as a form of cell death that is uncontrolled and
lacks underlying signaling events resulting in dramatic irreversible alterations in essential cell
parameters of metabolism and cell structure [141]. This might be true for cell death in response
to severe physical or chemical damage or adverse conditions; however, accumulating evidence
supports the notion that necrosis is a regulated process involving multiple developmental,
physiological, and pathological scenarios [142, 143]. For such a reason, it is called necroptosis
or programmed necrosis. Necroptosis is characterized by cytoplasmic and organelle swelling,
followed by the disruption of the cell membrane integrity, leading to the release of the cellular
contents into the extracellular milieu, which may result in an inflammatory response. Unlike
apoptosis, the nuclei of necrotic cells remain largely intact [144]. Necroptosis can be induced
by inhibition of cellular energy production, generation of ROS, imbalance of intracellular
calcium flux, or extracellular cell death signals, which are also able to induce apoptosis,
suggesting that different types of cell death may share, at least in part, common mechanisms.
In this sense, time and intensity of stimulus may determine the type of cell death. Indeed, one
study showed that depending on glutathione depletion and oxidative stress level, apoptosis
can switch to necroptosis [145].
4.1. Molecular mechanisms of necroptosis
Necroptosis can be triggered by ligands through numerous death receptors, including TNFR1
and TNFR2, TRAILR1 and TRAILR2, CD95 (Fas), and toll-like receptors (TLRs) [146-148], as
well as by different kinds of physical-chemical stress stimuli, such as anticancer drugs, ionizing
radiation, and calcium overload [149].
New Frontiers in Cancer Chemotherapy — Targeting Cell Death Pathways
http://dx.doi.org/10.5772/61260
105
The death receptors are activated by their ligands followed by the recruitment and activation
of caspase 8 that trigger the apoptosis in the absence of NF-κB survival pathway. However,
under conditions that fail to trigger apoptosis, necroptosis may be an alternative cell death
pathway. As shown in Figure 3, in the context of TNFR1 signaling, TNFα activates TNFR1,
which in turn induces the recruitment of RIP1 kinase and other proteins, including TRADD,
TRAF2, and cIAP1/2, to form a transient molecular complex referred to as complex I [144]. In
complex I, RIP1 is rapidly modified by k63-linked polyubiquitination mediated by E3 ligases,
cIAP1, and cIAP2. The ubiquitination of RIP1 serves as a platform to dock additional signaling
molecules, IKK complex, key mediators that lead to the activation of the canonical NF-κB
signaling, or inflammatory pathways [150-152]. RIP1 can be subsequently deubiquitinated by
the enzyme cylindromatosis (CYLD) [153] and, together with proteins involved in cell death
signaling, form complex II, which comprises as key components RIP1, TRADD, FADD, and
caspase 8 [154]. The formation of complex II initiates the cell death signals, and the cell death
via apoptosis or necroptosis is determined at this step. In the absence of cIAP1 or FLIP, RIP1,
FADD, and caspase 8 form complex IIa to activate the caspase cascade and to induce apoptosis
[31]. However, when caspase 8 activation is inhibited due to genetic or pharmacological
inhibition, RIP1 together with RIP3 forms a complex that leads to the necroptotic signal
transduction pathway [155]. This RIP1/RIP3-containing cytoplasmic necroptotic protein
complex is called complex IIb (also known as necrosome), which constitutes a key molecular
platform of necroptosis. RIP1 and RIP3 can phosphorylate reciprocally in an autocrine/
paracrine manner, leading to the activation of their kinase activity [32, 156].
The mixed lineage kinase domain-like protein (MLKL), also detected in complex IIb, is the
most downstream effector of necroptosis so far identified [157, 158]. The N-terminal domain
of MLKL is required for assembly of higher order structure and recruitment of MLKL to the
plasma membrane, followed by permeabilization of the plasma membrane [159-161]. The C-
terminal pseudokinase domain of MLKL interacts with RIP3 and is phosphorylated by the
latter at the threonine 357 and serine 358 residues, and these phosphorylation events are critical
for necroptosis [161]. In fact, blocking MLKL activity leads to necroptosis inhibition. Besides
the plasma membrane, activated MLKL may translocate to intracellular membranes, possibly
leading to the permeabilization of the ER, mitochondria and lysosome [160]. In addition, RIP3
phosphorylates MLKL, which in turn activates the mitochondrial phosphatase phosphogly‐
cerate mutase 5 (PGAM5), a central downstream effector of the necrosomal complex. PGAM5
in turn initiates the dephosphorylation of GTPase dynamin-related protein 1 (DRP1), a
mitochondrial fission regulator, which leads to the mitochondrial fission and mitochondrial
fragmentation. This process is essential for the necroptotic pathways, as necrosis cannot occur
without mitochondrial fission [162].
In addition to necrosome, another necroptosis-inducing complex referred to as ”ripoptosome”
has also been identified [163, 164]. Under normal conditions, the core components of this
complex, namely, RIP1, FADD, and caspase 8, are ubiquitinated by IAPs, which leads to the
degradation of these core components and thereby suppresses ripoptosome formation (Figure
3). However, when exposed to Smac mimetics or genotoxic stress, IAPs are downregulated,
resulting in the spontaneous formation of the ripoptosome and triggering of caspase-8-
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mediated apoptosis or caspase-independent necroptosis. There are three signaling pathways
initiated following ripoptosome formation. (1) The formation of caspase 8 homodimers within
the complex results in full catalytic activity and thus apoptosis. (2) The formation of caspase-8-
cFLIPL (long splice form of FLIP) heterodimers instead results in limited catalytic activity,
which is able to cleave RIP1 but is not sufficient to trigger apoptosis, leading to ripoptosome
disassembly and cell survival. (3) The formation of caspase-8-cFLIPS (short splice form of FLIP)
heterodimers predominates within the complex, and caspase 8 activation and RIP1 cleavage
are prevented, thereby promoting ripoptosome formation. This in turn leads to the mode of
cell death instead of being switched to necroptosis [163, 164].
A schematic overview of major signal transduction pathways induced by various stimuli and
ultimately leading to necroptosis can be found in the review article (Figure 1) by Kaczmarek
et al. [165].
Figure 3. TNFR1 engagement- or genotoxic stress-induced formations of divergent signaling complexes, leading to the
activation of NF-κB, apoptosis and necroptosis. Binding of ligands to receptors leads to the intracellular formation of
complex I. Lys63-linked polyubiquitination of RIP1 (in complex I) by cIAP ligases results in cell survival through the
activation of NF-κB and MAPKs. Deubiquitination of RIP1 by CYLD or inhibition of cIAP proteins leads to the conver‐
sion of complex I to complex IIa, activating the caspase cascade for apoptosis induction. Under conditions where cas‐
pase 8 activity is inhibited or RIP3 is highly expressed, RIP1 interacts with RIP3 to form complex IIb (necrosome),
which mediates necroptosis. The formation of complex IIb requires the kinase activity of RIP1. RIP3 and MLKL are
phosphorylated in complex IIb and translocated to the plasma membrane, where the complex mediates membrane
permeabilization. In addition, the downregulation of IAPs by Smac mimetics or genotoxic stress results in the sponta‐
neous formation of the ripoptosome, which can trigger caspase-8-mediated apoptosis or caspase-independent necrop‐
tosis.
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4.2. Regulation of necroptosis
4.2.1. FLIP and necroptosis
cFLIP molecule has been shown to be able to modulate the activation of procaspase 8 and
thereby prevents the apoptosis mediated by death receptors [166]. In the cytoplasm, RIP1 can
form complex with FADD, caspase 8, and TRADD (further referred to as ripoptosome)
following stimulation of T-cell receptor, TLR3, or TRL4. Remarkably, in response to genotoxic
stress (DNA damage), the spontaneous formation of the ripoptosome occurs independent of
death receptor activation [4, 144, 156, 163]. The ripoptosome can induce caspase-dependent or
caspase-independent cell death, depending on the cellular context or differential regulation of
caspase 8 by cFLIP. The cleavage of RIP1 in the ripoptosome complex by caspase 8 homodimers
triggers the downstream activation of effector caspases, leading to the induction of apoptosis.
Further, ripoptosome-mediated cell death or necroptosis also depends on the type of FLIP
isoform. The caspase 8/FLIPL heterodimers may induce RIP cleavage, thus leading to ripop‐
tosome disassembly and necroptosis inhibition, whereas caspase 8-/cFLIPS lacks proteolytic
activity necessary for RIP1 degradation, thus leading to necroptosis induction via RIP1 and
RIP3 [164]. Therefore, it is possible to divert cells to undergo apoptosis via the inhibition of
necroptosis through the modulation of ratio of FLIPL to FLIPS. Indeed, previous studies have
demonstrated that cFLIP protects cIAP antagonist-treated cells from Fas-induced cell death,
which involves both apoptosis and necroptosis [167]. cFLIPL inhibits the formation of the cell
death-inducing “ripoptosome, ” which functions in TLR3-induced apoptosis and necroptosis
[164]. Furthermore, siRNA-mediated silencing of cFLIPL sensitizes cells to TNF-induced RIP1/
RIP3-dependent necroptosis [168]. Therefore, FLIP plays a pivotal role not only in the regula‐
tion of apoptosis but also in necroptosis via the formation of ripoptosome and by switching
between apoptotic and necroptotic mechanism.
4.2.2. IAPs and necroptosis
The members of the IAP protein family exhibit E3 ubiquitin ligase activity and are character‐
ized by BIR domains that bind the active sites of caspases and inhibit proteolytic function [169].
During the intrinsic pathway of apoptosis, Smac/DIABLO is released from mitochondria to
cytosol thereby releases the caspases from the trap of IAP, leading to the activation of caspases
followed by apoptotic cell death. Smac protein was shown to induce the autodegradation of
cytosolic IAP1 and IAP2, allowing the formation of a caspase-8-activating complex consisting
of RIP1, FADD, and caspase 8 [170]. Several mammalian IAPs may utilize ubiquitination to
regulate their own stability. It has been recently found that Chal-24-induced autophagy
activation can result in the degradation of c-IAP1 and c-IAP2 and the formation of ripopto‐
some, thus contributing to necroptosis induction [171]. Remarkably, in the absence of IAPs
and under conditions where caspases are blocked, necroptosis can be stimulated via RIP1 and
its downstream kinase [172]. It has been demonstrated that loss of cIAPs promotes the
spontaneous formation of ripoptosome induced by genotoxic stress or TLR3 stimulation
through poly (I:C), a synthetic homologue of virus-derived double stranded DNA. Such event
occurs independently of death receptor stimulation and is suppressed by the cIAP1 or cIAP2
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that cause RIP1 ubiquitination and degradation [164]. FLIPL knockdown is able to enhance
ripoptosome aggregation, thus sensitizing cells to etoposide or TLR3-mediated cell death. The
role played by ripoptosome is complex since it can stimulate caspase-8-mediated apoptosis or
caspase-independent necroptosis depending on the cell types [163].
4.2.3. Regulation of necroptosis by caspase 8 activity
The concept of apoptosis blocking necrosis by caspase activity was firstly proved in 1998 by
the finding that the pharmacological inhibition of caspase activity sensitizes TNF-mediated
necrotic cell death in L929 cells [173]. Since then, this concept has been accepted as an estab‐
lished theory. Indeed, zVAD-fmk, a pan-caspase inhibitor, has been widely used to induce
necroptosis in a variety of cell lines as well as in mice models [173, 174]. Among the caspases,
caspase 8 is responsible for the switching between apoptosis and necroptosis [174]. Necroptosis
but not apoptosis was observed in caspase-8-deficient Jurkat cell lines in response to Fas and
TNFR stimulation. In vivo studies have also shown that caspase-8-deficient mice have signifi‐
cant necroptotic death, leading to embryonic lethality, which support the roles of caspase 8 in
blocking necroptosis. T-cell- or intestinal epithelial cell-specific deletion of caspase 8 in mice
also exhibited severe necroptotic features, inducing immunodeficiency or terminal ileitis,
respectively [175, 176].
The critical roles of caspase 8 on necroptosis are known to induce the cleavage of RIP1 and
RIP3 [31, 177]. Therefore, cells treated with caspase inhibitor or deficient in caspase 8 increase
the RIP1-RIP3 complex formation as well as necroptosis [156, 172, 178]. In addition, CYLD was
recently identified as a target of caspase 8 and a critical mediator. Caspase 8-mediated CYLD
cleavage at Asp215 prevents necroptosis, whereas the expression of mutant CYLD (D215A),
which is resistant to caspase 8-mediated cleavage, enhances necrosome formation and
necroptosis [178].
4.2.4. RIP1/RIP3 and necroptosis
RIP1  and  RIP3  are  key  signaling  molecules  in  inducing  necrosis  and  are  regulated  by
caspases and ubiquitination. The activity of RIP1 is specifically associated with necrosis and
not with apoptosis, which is demonstrated by use of Necrostatin-1 (Nec-1) that specifical‐
ly blocks the kinase activity of RIP1 [179]. Nec-1 inhibits TNF-induced necrosis in L929 cells
and  FasL-induced  necrosis  in  Jurkat  cells  that  were  pretreated  with  caspase  inhibitor
zVADfmk or  deficient  in  FADD [180].  In  addition  to  RIP1,  RIP3  kinase  activity  is  also
involved  in  caspase-independent  cell  death  [177],  and  it  has  become  clear  that  RIP3
determines cells to undergo necrosis in response to TNF treatment [32, 156, 172]. In contrast
to RIP1, RIP3 is not required for TNF-induced NF-κB activation [156, 181]. RIP1 activity is
essential  for  necrosome  formation  and  its  C-terminal  RHIM  domain  (RIP  homotypic
interaction  motif),  allowing  homotypic  interaction  with  RIP3  to  from  a  TNF-induced
complex, which is important for stabilizing the necrosome [182]. Under necrotic cell death
conditions,  RIP3  also  binds  to  other  metabolic  enzymes,  such  as  the  cytosolic  glycogen
phosphorylase (PYGL), the cytosolic glutamate-ammonia ligase (GLUL), and the glutaminol‐
ysis-initiating  enzyme GLUD1,  which  positively  modulates  RIP3  enzymatic  activity  [32,
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182].  These interactions result  in glutamine production and regulate glycogenolysis.  The
knockdown of PYGL, GLUL, or GLUD1 partially reduced the degree of TNF- and zVAD-
fmk-mediated ROS production and necrosis. It seems that both RIP1 and RIP3 are respon‐
sible for an increased cellular metabolism of carbohydrate and glutamine, leading to higher
ROS formation  and  subsequent  necrotic  cell  death  [182,  183].  The  activity  of  caspase  8
inhibits the necrotic cell death, likely by the cleavage of RIP1 and RIP3 [184], and down‐
stream,  through caspases  3  and 7  activation and poly-ADP-ribose  polymerase  (PARP)-1
[185].  Again,  this  demonstrates the importance of  RIP1/3 and the enhanced ROS forma‐
tion during the inhibition of caspases for the subsequent induction of necrosis [185-187].
5. Targeting cell death pathways in cancer treatment
5.1. Activating apoptosis in cancer treatment
5.1.1. TNF-Related Apoptosis-Inducing Ligand (TRAIL)
The TRAIL has been considered as a promising anticancer drug since it was found that TRAIL
preferentially triggers cell death in cancer cells compared to normal cells. Furthermore, unlike
TNF and FasL, TRAIL and antibodies against the TRAIL receptors were confirmed to be well
tolerated and safe in nonhuman primates even at relatively high concentrations [28, 188].
Recombinant human TRAIL has been shown to have the capacity to induce apoptosis in a
variety of cancer cells in vitro and in tumor xenografts [11]. TRAIL receptor agonists, including
recombinant TRAIL, as well as humanized antibodies against TRAIL receptors have been
evaluated in clinical trials [189-191]. However, several clinical trials using such drugs as single
agents to induce cancer cell death did not recapitulate the promising results obtained in animal
studies, which might be due to insufficient cross-linking of TRAIL receptors by the available
TRAIL agonists. This has led to the investigation of TRAIL-based combination therapies to
maximize antitumor activity. It has been shown that both conventional chemotherapy with
DNA damaging agents and radiotherapy induce the expression of TRAIL receptors in response
to DNA damage, thus suggesting a potential synergistic effect when combining these therapies
with TRAIL-targeted treatment [188, 192]. For example, histone deacetylase (HDAC) inhibitors
can induce the expression of TRAIL, thereby leading to the apoptosis in acute myelogenous
leukemia (AML) [193]. HDAC inhibitors enhance the synthesis of several proteins involved in
TRAIL signaling, such as DR5, and are able to sensitize the TRAIL-resistant cancer cells when
combined with TRAIL treatment [194, 195]. In addition, enhanced assembly of the TRAIL DISC
has been proposed to confer increased sensitivity in TRAIL-based combination therapies [196].
Many cytotoxic chemotherapeutic agents have been shown to induce the stabilization of p53
tumor suppressor protein in response to DNA damage and other cellular stresses, which
transcriptionally activates DR5 and other proapoptotic proteins that synergizes with TRAIL.
Therefore, TRAIL combination with such agents could be a useful therapeutic strategy for
cancer.
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However, the efficiency of TRAIL-based therapy in human cancers is not satisfactory due to
the existence of both agonistic receptors (TRAIL-R1 and TRAIL-R2) and antagonistic decoy
receptors (TRAIL-R3 and TRAIL-R4) in human cells. This implies that recombinant TRAIL
ligand is capable of eliciting proapoptotic or antiapoptotic signals depending on the availa‐
bility of these different receptors on the cell surface. Moreover, in some cancer cells, TRAIL
can induce the activation of NF-κB, thus promoting cancer cell survival rather than apoptosis
[188, 197]. Thus, the context-based effect of TRAIL signaling may explain the lack of efficacy
seen in recent studies of TRAIL-targeted anticancer therapy. It was reported that TRADD is a
key component that activates NF-κB in TRAIL signaling, and siRNA-mediated knockdown of
TRADD in cancer cells sensitizes them to TRAIL-induced apoptosis. Therefore, TRADD may
serve as a target for sensitizing cancer cells to TRAIL cytotoxicity [198].
5.1.2. Bcl-2 family
Antiapoptotic proteins of the Bcl-2 family, such as Bcl-2, Bcl-xL, and Mcl-1, are promising
targets for anticancer drug development because they play a crucial role in regulating
apoptosis, and the overexpression of these proteins is frequently observed in a variety of tumor
types. Currently, three main strategies targeting this pathway are under investigation: (1) small
molecules that affect gene or protein expression, (2) silencing of the upregulated antiapoptotic
proteins with antisense oligonucleotides, and (3) BH3-only peptides or synthetic small
molecule inhibitors interfering with Bcl-2 like protein function. With regard to transcription
silencing, studies have shown that, depending on the tissue origin of the malignancy, the
expression of Bcl-2 or Bcl-xL can be downregulated in specific types of cancer and leukemia
cells by small molecule drugs that modulate the activity of retinoic acid receptors (RAR),
retinoid X receptors (RXR), peroxisome proliferator-activated receptors (PPAR), vitamin D
receptors (VDR), and certain other members of the steroid/retinoid superfamily of ligand-
activated transcription factors (SRTFs). Consequently, RAR and RXR ligands as well as PPAR
modulators have been developed and evaluated for the treatment of some types of leukemia,
lymphoma, and solid tumors, such as breast and prostate cancers [23, 199]. HDAC inhibitors,
which function as transcriptional repressors via interaction with retinoid receptors and other
transcription factors, can also favorably modulate the expression of Bcl-2 or Bcl-xL in some
tumor lines [23]. These findings provide the basis for developing novel strategies for cancer
treatment by suppressing the expression of antiapoptotic Bcl-2-family genes in cancer.
Besides  the  chemical  compounds,  antisense  oligonucleotides  have  also  been  studied  to
knockdown the Bcl-2  family  of  antiapoptotic  proteins.  One agent  that  is  currently  most
advanced in clinical trials is Genasense (also known as oblimersen or G3139), which is a
synthetic, 18-base, single-stranded phosphorothioate oligonucleotide targeting Bcl-2 mRNA
that was developed by Genta Inc. (Berkeley Heights, NJ). More precisely, Genasense is in
phase II and phase III clinical trials treating a wide variety of adult and childhood tumors
[200]. In addition, treatment with Genasense markedly improved the antitumor activity of
many chemotherapeutic agents, such as taxanes, anthracyclines, alkylators, doxorubicin, or
dacarbazine [201-203]. In a phase III clinical trial, Genasense in combination with dacarba‐
zine was reported to significantly improve multiple clinical outcomes and increase overall
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survival  in  patients  with  advanced melanoma [203].  Furthermore,  a  bispecific  antisense
oligonucleotide selectively targeting Bcl-2 and Bcl-xL has been reported to simultaneously
downregulate  the  expression  of  both  Bcl-2  and Bcl-xL  and enhance  chemosensitivity  in
various cancer cells [204-206].
Intracellular stress signals can activate BH-3 only proteins to antagonize antiapoptotic Bcl-2
family members. An attempt to mimic the BH3-only action was the development of BH3
mimetic compounds containing exposed BH3 domain that occupy the BH3-binding site on
Bcl-2 or Bcl-xL, abrogating their antiapoptotic functions. ABT-737 and its oral derivative,
ABT-263 (also called navitoclax), are among the first promising BH3 mimetics in cancer therapy
[207, 208]. Both drugs avidly bind and inhibit Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1 or A1.
ATB737 has been shown to be effective as a single agent against certain lymphomas and small
cell lung cancer in vitro and in vivo [207] and against non-small cell cancer [209]. ATB737 has
also been reported to have synergistic cytotoxicity with conventional chemotherapeutic
agents, and other targeted agents, including tyrosine kinase inhibitor, EGFR inhibitor, MEK
inhibitor, and BRAF inhibitor, to reverse drug resistance and kill tumor cells [210, 211]. Initial
clinical trials have demonstrated a significant antitumor activity of ATB263 as a single agent
in the treatment of B-cell malignancies, especially CLL [212]. Several preclinical studies have
shown promising effects of combinatorial use of ATB263 with conventional cytotoxic agents
or targeted therapy in both solid tumor and hematologic malignancy models [210, 213].
However, the practical use of ATB263 is limited due to its propensity to induce acute throm‐
bocytopenia. ABT-199, a newer BH3 mimetic that specifically targets Bcl-2, has been shown to
suppress the growth of Bcl-2-dependent tumors in vitro and in vivo without causing thrombo‐
cytopenia since it does not antagonize Bcl-xL, which is critical for platelet survival [214-216].
Also, ATB263 has been demonstrated to enhance the antitumor activity when administrated
in combination with other chemotherapeutic agents [217, 218]. Other BH3 mimetics, such as
WEHI-539, BXI-61, BXI-69, Obatoclax, S1, JY-1-106, Gossypol, and its derivatives (apogossypol,
apogossypolone, and TW-37) as well as selective Mcl-1 inhibitors, have been developed, and
their antitumor effects have also been investigated or are under investigation (reviewed by
Vogler [211]).
5.1.3. IAP inhibitors
IAPs play a critical role in the control of cell survival and death by regulating key signaling
events such as caspase activation and NF-κB signaling that makes them become attractive
molecular targets. XIAP has been reported to be the most potent inhibitor of apoptosis among
all IAPs, consequently targeting XIAP using antisense oligonucleotides, or siRNA molecules
have been developed in the treatment of cancer. Indeed, targeting XIAP by antisense oligo‐
nucleotides or siRNA has been demonstrated to be able to induce apoptosis and sensitize
cancer cells to death receptor- and chemotherapeutic agents-induced cell death in a variety of
cancer in vitro and in vivo [219-223]. Similarly, the siRNA-mediated downregulation of other
IAPs, such as cFLIP and survivin, has also been shown to enhance chemotherapy activity in a
range of cancers [224-226]. In addition, some chemical compounds, for example, mTOR
inhibitors and HDAC inhibitors, can suppress the cFLIP expression via blocking its translation
and transcription, respectively [226, 227].
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Another approach for targeting IAPs is to disrupt IAP binding to caspases by small molecule
IAP antagonists. IAP antagonists bind to the BIR2 or BIR3 domain of XIAP, cIAP1, and cIAP2,
leading to the activation of caspase and induction of apoptosis [228]. Most of IAP antagonists
are Smac mimics, and in addition to monovalent compounds that contain one Smac-mimicking
unit, bivalent or dimeric IAPs have also been developed, which consists of two Smac-mim‐
icking units that are connected via a chemical linker [229]. When used as a single agent, IAP
antagonists can only effectively trigger cell death in a small subset of human malignancies,
suggesting that IAP antagonist-based combination therapies might be required for the effective
treatment of a majority of tumors. A variety of chemotherapeutic agents (including doxoru‐
bicin, etoposide, gemcitabine, paclitaxel, cisplatin, vinorelbine, SN38, 5-fluorouracil (5-FU),
cytarabine, and HADC inhibitor vorinostat), death receptor agonists, and signal transduction
modulators (including proteasome inhibitors, various kind of kinase inhibitors and monoclo‐
nal antibodies targeting growth factor receptor) have been shown to act cooperatively with
IAP antagonists to enhance antitumor activity in vitro and in preclinical models of cancers
[230-236]. For instance, beneficial synergistic effects were observed when IAP antagonists were
used in combination with other compounds, such as bortezomib, TRAIL, or DNA damaging
agents, such as melphalan, to reduce tumor burden in multiple myeloma models [237]. Along
these lines, LBW242 was also highly beneficial in an FLT3-mutated AML xenograft mouse
model when administered along with the protein kinase inhibitor PKC412 [238]. A recent study
depicted the combinatorial effect of Pak1, a downstream Rac effector, inhibition on IAP
antagonist treatment in NSCLC cell lines, rendering these cells hypersensitive to apoptotic cell
death [239]. The development of combination therapy is warranted as it promotes better
patient survival, as shown in a metastatic breast cancer Phase III clinical trial [240]. Combina‐
tion therapy might promote synergistic effects leading to low drug dosage, as well as sup‐
pressing resistance to therapy if multiple cell survival pathways are targeted at once, although
the probability of toxicity is also increased [241]. Fortunately, clinical trials with IAP antago‐
nists have not showed any dose-limiting toxicity [242].
5.2. Targeting autophagy in cancer treatment
Therapeutic targeting of the autophagy pathway as a new anticancer strategy has been under
extensive investigation. Since autophagy can play roles in tumor growth depending on the
context, such as tumor type or stage, both of the autophagy-enhancing and autophagy-
inhibiting agents may elicit beneficial effects in the treatment of cancer.
5.2.1. Inhibition of autophagy
High levels of autophagy are commonly observed in tumor cells following anticancer therapy.
For example, chemotherapeutic agents (e.g., doxorubicin, temozolomide, camptothecin, and
tamoxifen), HDAC inhibitors (e.g., SAHA), tyrosine kinase inhibitor (e.g., imatinib, sorafenib),
and monoclonal antibody (e.g., trastuzumab) have all been demonstrated to induce autophagy
in a variety of tumor cells [243-248]. Furthermore, a number of studies have shown that genetic
knockdown of ATGs or pharmacological inhibition of autophagy can effectively promote cell
death induced by various anticancer agents in many cancer lines and in multiple tumor models
[249-252]. These findings suggest that the activation of autophagy is a protective strategy for
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tumor cells to avoid being entirely killed by anticancer agents. The prosurvival ability of
autophagy renders tumor cells resistant to anticancer agents, which greatly compromises
curative efficacy of chemotherapy. In these contexts, the inhibition of autophagy can be a
promising strategy to reestablish or increase the sensitivity of tumor cells to therapeutic agents.
The common inhibitors of autophagy can be categorized into three types according to their
action mechanisms: (1) inhibit the formation of autophagosome via restraining the recruitment
of Class III PI3K to the membrane, such as 3-methyladenine (3-MA) and Wortmannin; (2)
prevent the degradation of proteins within autophagosome by disrupting lysosomal function,
such as chloroquine (CQ) and its analog hydroxychloroquine (HCQ); and (3) intervene in the
fusion of autophagosome with lysosome, such as bafilomycin A1 (BafA), a direct inhibitor of
vacuolar ATPase [253].
CQ and its derivative HCQ are the most common autophagy inhibitors used in clinical trials.
Preclinical studies have shown that CQ and HCQ are equipotent at autophagy inhibition and
potentiate the anticancer effects of different drugs both in vitro and in vivo. For example,
Amaravadi et al. reported that in a Myc-induced lymphoma mouse model, QC and HCQ
significantly enhance the cytotoxic effects of p53 expression and alkylating agents and
substantially impair the recurrence of tumor after chemotherapy [254, 255]. In chronic
myelocytic leukemia (CML) cell lines, the inhibition of autophagy by CQ markedly augments
the cell death induced by imatinib, a tyrosine kinase inhibitor that is a first-line therapeutic
agent for BCR/ABL-positive CML [256]. CQ has also been shown to promote the cytotoxic
effects of SAHA, an HDAC inhibitor, to overcome imatinib-resistant CML cells [246]. In a colon
cancer xenograft model, CQ in combination with vorinostat was shown to significantly reduce
tumor burden and increase apoptosis [257]. Similarly, CQ enhances the anticancer effect of the
saracatinib, an src inhibitor, in a xenograft mouse model of prostate cancer [258]. Currently,
phase I/II clinical trials are ongoing to evaluate the potential benefits of CQ and HCQ in
combination with standard cancer therapies for a variety of cancers [259], and these clinical
trials are listed at http://www.clinicaltrial.gov/.
In addition to CQ and its derivatives, other potential autophagy inhibitors have also been
studied for their anticancer efficacy in vivo and in vitro, including 3-MA, BafA, monensin, and
pepstatin A [260-262]. For example, the inhibition of autophagy by 3-MA increases cell death
induced by 5-fluorouracil (5-FU) in colon cancer xenograft model [263] as well as enhances
cytotoxicity induced by imatinib in glioma cell lines [264]. BafA in combination with tyrosine
kinase inhibitors, such as imatinib, nilotinib, or dasatinib, significantly increase cell death in
CML cells [256]. However, it must be remembered that the cytotoxic effects of these different
agents might not be solely due to the inhibition of autophagy; targeting key autophagy proteins
would be a more potent and specific approach. These include ULK1, Beclin 1, or ATG proteins.
5.2.2. Induction of autophagy
Although the concept of “autophagic cell death” in mammalian cells remains largely contro‐
versial, studies do show that autophagy is required for the efficient killing of tumor cells in
certain circumstances [252]. Certain tumor cells become highly resistant to apoptosis and
chemotherapy by overexpression of Bcl-2 or Bcl-xL, lack of Bax and Bak, loss of Beclin 1, or
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exposure to pan-caspase inhibitors [76]. Most anticancer drugs exhibit limited effect on this
subset of tumor cells. Fortunately, studies have demonstrated that the induction of autophagy
may be an alternative way for cancer treatment when apoptosis is blocked [265, 266]; however,
the conditions under which autophagy can function as a primary cell-death mechanism remain
to be defined.
Among the potential targets in autophagy, Akt-mTOR pathway is the most investigated one.
mTOR inhibitors, including rapamycin and its analogs everolimus (RAD-001), temsirolimus
(CCI-779), and deforolimus (AP-23573), have been developed and studied for their ability to
induce autophagy and cell death. Everolimus and temsirolimus have been approved for the
treatment of renal cell carcinoma and mantle cell lymphoma [267]. Rapamycin has been shown
to inhibit cell growth and initiate cell death in mantle cell lymphoma cell lines and various
primary tumor cells, such as malignant gliomas, breast cancers, renal cell carcinomas, non-
small cell lung cancers, and cervical and uterine cancers [13, 253]. Everolimus induces massive
autophagy in leukemia [268], in advanced pancreatic cancer [269], and in many other cancers
[270], accompanied by reduced tumor burden. In addition, everolimus in combination with
etoposide, cisplatin, or doxorubicin display synergistic effects without significant increase in
toxicity [271]. However, rapamycin and its analogs would inevitably activate Akt kinases,
which associate with the induction of insulin receptor substrate-1, jeopardizing the antitumor
effects of these mTOR inhibitors [272]. Other inhibitors, including ATP-competitive inhibitors
of both mTORC1 and mTORC2 as well as the dual PI3K-mTOR inhibitor NVP-BEZ235 [273,
274], have exhibited more potent capacity to induce autophagy in cancer cells [275, 276].
Antiapoptotic Bcl-2 family members are frequently overexpressed in many human tumor
types, rendering tumor cells resistant to apoptosis. Bcl-2 family members are important
regulators involved in both apoptosis and autophagy. As a result, the modulation of Bcl-2
family proteins leads to not only apoptotic but also autophagic cell death. The underlying
mechanism of this effect reflects the fact that Bcl-2/ Bcl-xL proteins can bind and disrupt the
autophagic function of Beclin 1, which contains a BH3 domain [277]. This is notably the case
for BH3 mimetics (ABT737, ABT236, gossypol, obatoclax) that targets Bcl-2/Bcl-xL, thus
allowing Beclin 1 to be released to trigger autophagy [277, 278]. Obatoclax has been shown not
only to induce cell death on its own but also to potentiate the effects of other anticancer agents
such as the dual EGFR/HER2 inhibitor lapatinib, or HDAC inhibitors [279]. Although the
inhibitory effect affects both apoptosis and autophagy, the tumor cells preferentially undergo
autophagic cell death in apoptosis-defective cells. For example, doxorubicin primarily induces
autophagy at low doses while apoptosis at high doses, and the combination of Bcl-2 siRNA
treatment with a low dose of doxorubicin enhances the autophagic response, tumor growth
inhibition, and cell death [126].
In pursuit of new drugs to selectively kill renal cell carcinoma (RCC), Giaccia and colleagues
identified a compound, STF-62247, that strongly induced autophagy and massive vacuoliza‐
tion in VHL (a tumor suppressor gene lost in 75% of RCCs)-deficient RCC cells with no
apparent apoptosis induction. Blocking autophagy using ATG5 or ATG7 siRNA or 3-MA
prevents STF-62247-induced cell death, indicating that this compound induces cell death by
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autophagy in VHL-deficient RCC cells [280]. In addition, other autophagic cell death-inducing
anticancer agents have been developed and studied [279].
5.3. Modulation of necrosis for cancer treatment
The accumulating data have indicated that necrotic cell death can be activated to induce the
damage of tumor tissue. DNA-damaging agents are the most widely used and effective
chemotherapeutic approach for cancer treatment, which has been shown to be able to stimulate
a regulated form of necrosis [281]. The PARP is activated in response to DNA damage, which
facilitates the access of DNA repair enzymes to damaged DNA. The hyperactivation of PARP
depletes cytosolic nicotinamide adenine dinucleotide (NAD) and induce necrosis [282], which
may lead to selectively killing tumor cells because highly proliferating tumor cells depend on
cellular NAD to generate energy through aerobic glycolysis. PARP-mediated necrosis may
explain the phenomenon that neither Bax/Bak nor p53 deficiency impedes cell death in
response to DNA-damaging agents. Jouan-Lanhouet et al. found that the death receptor ligand
TRAIL induces necroptosis in human HT29 colon and HepG2 liver cancer cells via RIP1/RIP3-
dependent PARP1 activation and depletion of cellular ATP levels, suggesting PARP1 activa‐
tion as an effector mechanism downstream of RIP1/RIP3 [283].
There are more and more compounds and anticancer drugs that have been demonstrated to
induce cancer cell death through necrosis, such as shikonin, FTY720, staurosporine, derivatives
of amiloride (5-benzylglycinyl-amiloride and glycinyl-amiloride), and BI2536 (a small
molecule inhibitor of the mitotic kinase Plk1). Most of them were not necessarily designed in
a mechanism-based fashion but were only later found to induce necrotic features in the dying
cells [284-289]. Shikonin, a naturally occurring naphthoquinone, was reported to induce
necroptotic cell death in cancer cells that can be prevented by RIP1 inhibitor necrostatin-1, a
specific inhibitor of necroptosis. Moreover, shikonin-induced necroptosis can overcome drug-
and apoptosis-resistant cancer cell lines overexpressing P-glycoprotein, MRP1, BCRP, Bcl-2,
or Bcl-xL [284, 285]. FTY720, a sphingolipid analogue drug that mimics ceramide, was shown
to target the I2PP2A/SET oncoprotein, which results in the activation of tumor suppressor
PP2A and subsequently induces RIP1-mediated necroptotic cell death and tumor growth
inhibition [286]. Staurosporine, an inhibitor of a broad spectrum of protein kinases, has been
shown to induce necroptosis in leukemia cells when caspase activation is inhibited. The
induction of necroptosis was blocked by several pharmacological inhibitors, including
necrostatin-1, HSP90 inhibitor geldanamycin, MLKL inhibitor necrosulfonamide, and a
cathepsin inhibitor CA-074-OMe, which has been demonstrated to rescue the caspase-
independent necrotic cell death of leukemia cells treated by staurosporine [289]. Other
anticancer agents have also been shown to induce necroptosis via different mechanisms.
Bonapace et al. reported that obatoclax (GX15-070), a putative antagonist of Bcl-2 family
members, could overcome glucocorticoid resistance in childhood acute lymphoblastic
leukemia (ALL) through the induction of autophagy-dependent necroptosis, which bypassed
the block in mitochondrial apoptosis [290]. Obatoclax was also shown to promote the assembly
of the necrosome on autophagosomal membranes, thereby connecting obatoclax-induced
autophagy to necroptosis signaling pathways [291]. Coimmunoprecipitation assays demon‐
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strated that obatoclax promoted the physical interaction of ATG5, a constituent of autopha‐
gosomal membranes, with FADD, RIP1, and RIP3 as key components of the necrosome [291].
Small molecule inhibitors targeting IAPs such as Smac mimetics, which have been developed
to induce apoptotic cancer cell death, have been found to also engage necroptotic cell death.
He et al. first reported that, upon the inhibition of caspase activity, Smac mimetics in combi‐
nation with TNFα provoke a strong necroptotic response in Smac mimetic-resistant cancer
cells [172]. Similarly, Smac mimetic BV6 promotes TNFα-induced necroptosis not only in
leukemia cell lines deficient in caspase 8 or FADD but also in primary, patient-derived ALL
cells [292]. This Smac mimetic/TNFα-triggered necroptosis occurred in an RIP1-dependent but
caspase-independent manner in these leukemia cells lacking caspase 8 or FADD; however, in
FADD- or caspase-8-proficient leukemia cells, the same cotreatment of Smac mimetic and
TNFα induced apoptotic cell death [292]. This illustrates that Smac mimetic can prime
leukemia cells to TNFα-mediated cell death via either necroptosis or apoptosis depending on
the cellular context. Mechanistically, by promoting the degradation of cIAP proteins, Smac
mimetics stimulate the necrosome formation and promote necroptosis [293]. Furthermore, a
recent study demonstrated that Smac mimetic cooperates with demethylating agents to
synergistically induce cell death and can circumvent apoptosis resistance of AML cells by
switching to necroptosis [294].
Targeted toxins are fusion proteins that combine a targeting protein, such as a ligand for a
specific receptor, and a toxic peptide derived from a bacterial pathogen [295]. Diphtheria toxin
GM-CSF (DT-GMCSF) was shown to kill AML cells by simultaneously activating both caspase-
dependent apoptosis and caspase-independent necroptosis [296]. Interestingly, DT-GMCSF-
induced necroptotic cell death even occurred in apoptosis-resistant AML cells, indicating that
necroptosis may open new perspectives for cancer drug development in AML [296].
6. Conclusions and future perspectives
The dysregulation of the cell death process is closely related to cancer progression and
resistance to chemotherapy. The concept to therapeutically target apoptotic signal transduc‐
tion pathways has significant implications for cancer therapy since intact apoptosis programs
are critically required for the antitumor activity of most current cancer therapies that are used
in clinical oncology. The reactivation of apoptosis not only directly induces cell death in tumor
cells but also sensitizes tumor cells to other chemotherapeutic or targeted therapy agents.
However, given the wide variety of genetic and epigenetic defects that lead to apoptosis
resistance in most cancers, understanding the mechanism and regulation of other cell death
pathways in response to antitumor agents is important. Autophagy and necrosis are two
nonapoptotic cell death models that can be triggered as a consequence of cancer therapy and
may have overlapping but separable regulatory networks. Unlike apoptosis or necrosis,
autophagy has been shown to exert dual functions in cancers. On one hand, autophagy can
function as a survival pathway in response to anticancer agents; hence, autophagy inhibitors
may be used as adjuvants to standard cancer therapies. On the other hand, autophagy can lead
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to cell death in certain circumstances; thus, autophagy inducers may help to eradicate cancer
cells. As the effect of autophagy on cancer therapy varies depending on cell context such as
cell type, phases, and microenvironment, personalized pharmacotherapeutic strategies should
be adopted alone or most likely in combination with standard chemotherapeutic agents.
The success of compounds like the BH3 mimetics, Smac mimetics, TRAIL, and mTOR inhibi‐
tors in preclinical studies is proof that the reactivation of defective cell death pathways in
cancer cells is possible and can effectively eradicate tumor cells. Therefore, efforts should be
put to further delineate and identify regulatory components of the different cell death
pathways that can be targeted and manipulated to execute death. Understanding the crosstalk
between the different cell death pathways as well as between cell death and non-cell death
pathways in cancer is crucial to spot prospective convergence points between pathways.
Targeting the convergence points will allow the switching between pathways and improvi‐
sation of alternate means of inducing cancer cell death. For example, TNF signaling to the NF-
κB prosurvival and inflammatory pathway can be rerouted to the necroptotic pathway to
promote cell death just by modulating cIAP levels [163].
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